The CARAMAL study could not assess the effectiveness of rectal artesunate in treating suspected severe malaria.

BMC Med

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Published: March 2023

CARAMAL was a large observational study which recorded mortality in children with suspected severe malaria before and after the roll-out of rectal artesunate in Nigeria, Uganda and the Democratic Republic of the Congo. The results of CARAMAL have had a huge impact on public health policy leading to a World Health Organization moratorium on the roll-out of rectal artesunate. The conclusion reported in the abstract uses strong causal language, stating that "pre-referral RAS [rectal artesunate suppositories] had no beneficial effect on child survival". We argue that this causal interpretation of the study results is not justified. Data from the CARAMAL study inform chiefly on the strengths and weaknesses of referral systems in these three countries and do not inform reliably as to the beneficial effect of providing access to a known life-saving treatment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10060129PMC
http://dx.doi.org/10.1186/s12916-023-02776-zDOI Listing

Publication Analysis

Top Keywords

rectal artesunate
12
caramal study
8
suspected severe
8
severe malaria
8
roll-out rectal
8
caramal
4
study assess
4
assess effectiveness
4
effectiveness rectal
4
artesunate
4

Similar Publications

Recent updates in the WHO guidelines for malaria case management.

Sudan J Paediatr

January 2024

Independent Consultant, Lawrenceville, Georgia, USA.

This is a brief review that highlights recent updates in malaria case management. Recent WHO revisions include a new artemisinin-based molecule (artesunate-pyronaridine), revising the recommendations for treating uncomplicated malaria during the first trimester of pregnancy and optimising primaquine dose to prevent relapses. The review also highlights innovative ideas to improve the implementation of guidelines for severe malaria and pre-referral treatment with rectal artesunate.

View Article and Find Full Text PDF

Indigenous emergence and spread of C469Y artemisinin-resistant in Uganda.

Antimicrob Agents Chemother

August 2024

Malaria Research Unit, Institut Pasteur in Cambodia, Phnom Penh, Cambodia.

Article Synopsis
  • Artemisinin-based combination therapies (ACTs) have been the standard treatment for uncomplicated malaria in Africa for nearly 20 years, but recent studies indicate an increase in mutant parasites linked to reduced treatment effectiveness.
  • The Community Access to Rectal Artesunate for Malaria project studied 697 children with severe malaria in northern Uganda, finding that a significant mutation (C469Y) was more common after the introduction of rectal artesunate, suggesting it enhances resistance.
  • Genome analysis revealed that the C469Y mutation has an indigenous African origin and confirmed that parasites with this mutation show significantly reduced susceptibility to artemisinin, highlighting the urgent need for ongoing monitoring and adherence to treatment protocols to combat the rise of resistant strains.
View Article and Find Full Text PDF

Severe malaria intervention status in Nigeria: workshop meeting report.

Malar J

June 2024

National Malaria Elimination Programme, Public Health Department, Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria.

Nigeria accounts for 39% of global malaria deaths in children under 5 years of age and the effective management of severe malaria is a health priority. The Annual Nigeria Severe Malaria Stakeholders Workshop, held on the 5-6th of July 2023 in Abuja, Nigeria brought together representatives from 36 States, the Federal Capital Territory, and other key stakeholders to address the management of severe malaria across all levels of the health service. Aims were to provide updates and review progress on severe malaria activities, the burden of disease, commodity logistics management, and pre-referral national policy implementation as well as to disseminate research findings.

View Article and Find Full Text PDF

Defining the next generation of severe malaria treatment: a target product profile.

Malar J

June 2024

Medicines for Malaria Venture, Route de Pré-Bois 20, Post Box 1826, CH-1215, Geneva 15, Switzerland.

Background: Severe malaria is a life-threatening infection, particularly affecting children under the age of 5 years in Africa. Current treatment with parenteral artemisinin derivatives is highly efficacious. However, artemisinin partial resistance is widespread in Southeast Asia, resulting in delayed parasite clearance after therapy, and has emerged independently in South America, Oceania, and Africa.

View Article and Find Full Text PDF

Rectal artesunate: lives not saved.

Trans R Soc Trop Med Hyg

October 2024

Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, New Richards Building, Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG, UK.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!